Summary
Work History
Education
Skills
Scholarships and Achievements
Publications
References
Software
Overview
Languages
Timeline
Generic
Pannapa Pinweha

Pannapa Pinweha

Research Scientist II
Singapore

Summary

I have extensive experience in biochemistry, cancer cell biology, cancer metabolism, and the regulatory role of microRNAs in cancer, which I gained during my Ph.D. My work also includes developing ultrasensitive liquid biopsy tests for cancer diagnostics using multiplexed amplicon-based next-generation sequencing (NGS). Additionally, I have experience training research assistants and medical technologists, enabling them to perform specialized tasks and contribute effectively to ongoing projects.

Work History

Research Scientist II

Lucence Diagnostic Pte. Ltd.
7 2023 - Current
  • As research scientist II, I led the upgrade of the tissue biopsy NGS platform for cancer diagnosis, known as TissueHALLMARK. By utilizing DNA and RNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens, this test enables simultaneous interrogation of single nucleotide variants (SNVs), insertions and deletions (INDELs), copy number variations (CNVs), fusion transcripts, splicing variants, and exon skipping events associated with therapeutic applications or known to be linked with the development of specific cancer types.
  • I led the development of ctRNA NGS-based Test for Multi-Cancer Early Detection, intricately designed to detect cancer-associated alterations through ctRNA expression analysis using NGS techniques. It serves as a potent tool for early cancer detection across 20 different cancers.
  • I contributed to the upgrade of the NGS platform for blood cancer detection, known as HemeMARK. I participated in the design and execution of clinical validation for this assay.

Research Scientist I

Lucence Diagnostic Pte. Ltd.
11.2021 - 7 2023
  • As a research scientist I, I designed and developed a liquid biopsy next-generation sequencing (NGS) platform for circulating tumor RNA (ctRNA) diagnostic tools in cancer screening.
  • I developed a targeted RNA sequencing panel specifically to detect fusion genes from patient-derived circulating tumor RNA (ctRNA). In addition, I optimized workflows, validated assays, and developed a novel quality control feature for ctRNA analysis from clinical samples.
  • I led the technical transfer of the panel to the service department at Lucence Health in Singapore and California in 2022, where it was commercially launched under the name LiquidHALLMARK ctDNA and ctRNA.
  • I have experience in preparing validation documents and developing an upgraded pipeline for RNA expression analysis. Additionally, I have assisted in checking and troubleshooting various versions of bioinformatics pipelines to ensure optimal performance.
  • I have hands-on experience in clinical data curation, collaborating closely with software engineers to construct an in-house database for storing clinical information. In this role, I took charge of identifying inaccuracies, standardizing, and validating data to uphold its accuracy and reliability. Additionally, I conducted comprehensive clinical data analysis, focusing on large datasets related to lung and cholangiocarcinoma. This analysis aims to provide valuable clinical insights for our collaborators in Hong Kong and the United States.

Education

Ph.D. - Biochemistry (International Program)

Mahidol University
Thailand
04.2001 -

Ph.D. - Research Scholar

University of South Australia
Australia
04.2001 -

Bachelor of Science - Biology

Kasetsart University
Thailand
04.2001 -

Skills

Multiplexed amplicon-based next-generation sequencing (NGS)

Scholarships and Achievements

  • The best oral presentation award at the 8th Conference on Science and Technology for Youths, Bangkok, on the topic of Chemical composition of Siamese Crocodile (Crocodylus siamensis) Egg Yolk (2013).
  • I was awarded the King Bhumipol fund for outstanding students who have earned the highest overall GPA (3.89) in a major area of study (2012).
  • I have fully been supported by the Science Achievement Award (SAST) scholarship from the Thai Ministry of Education (2009 -2019).

Publications

  • Jonathan Poh, Yong Chai Ang, Jia Min Ho, Hao Chen, Chae Yin Cher, Michelle Pek, Mei Mei Chang, Sau Yeen Loke, Pannapa Pinweha, Ee Wern Kwong, Yee Fang Hum, Chwee Lim, Min-Han Tan (2024) Multi-cancer early detection (MCED) in circulating tumor DNA (ctDNA) using an ultrasensitive mutation-based amplicon next-generation sequencing (NGS) assay. Journal of Clinical Oncology 42 2024 (suppl 16; abstr e15042).
  • Gin Wai Kwok, Jonathan Poh, Chae Yin Cher, Pannapa Pinweha (2024) Utility of an Amplicon-Based ctDNA Platform for Advanced Cholangiocarcinomas (CCA) in Asia. Journal of Clinical Oncology 42 2024 (suppl 16; abstr e16206).
  • Y.F.Hum, J. Poh, Pinweha P., C.Y. Cher, J.M. Ho, M-H Tan, K.C. Ngeow (2023) Plasma Cell-free RNA Sequencing Enables Sensitive Detection of Lung Cancer. IASLC 2023 World Conference on Lung Cancer (September 09, 2023).
  • Z.Y. Wan, Y.T. Hee, H. Kaur, Pinweha P., Y. Choudhury, M-H Tan (2022) Peripheral T-Cell Receptor Repertoire Profiling in Non-small Cell Lung Cancer Using an Amplicon-Based Sequencing Assay. Journal of Thoracic Oncology, Vol.17, Issue 9, S569 (September 2022).
  • Choudhury Y., Pinweha P., Pho J., Lim J.S., Tan Min-Han (2022) Early detection of cancer using cell-free DNA (cfDNA) size analysis on a multiplexed amplicon-based next-generation sequencing (NGS) platform. Journal of Clinical Oncology 40, no.16_suppl (June 01, 2022) 3041-3041.
  • Pinweha P., Caroline A.P., Philip A.G., Xiaochun L., Chuayboonya P., Mongkolsiri P., Goodall G. and Jitrapakdee S. (2019) miR-143-3p targets Pyruvate Carboxylase expression and controls proliferation and migration of MDA-MB-231 cells. (IF=3.5) Arch. Biochem. Biophys., 677: 108169.
  • Pinweha P., Rattanapornsompong K., Charoensawan V. and Jitrapakdee S. (2016) MicroRNAs and Oncogenic Transcriptional Regulatory Networks Controlling Metabolic Reprogramming in Cancers. (IF= 4.67) Comput Struct Biotechnol J.,14: 223-233.

References

  • Chae Yin Cher, PhD. (Companion Diagnostic Team Lead), Lucence Diagnostic Pte. Ltd. 211 Henderson Rd., #04-02 Henderson Industrial Park, Singapore, 159552, +65 8809 9857, chaeyin.cher@lucence.com
  • Professor Gregory J. Goodall (Head, Gene Regulation Section), Centre for Cancer Biology, SA Pathology and University of South Australia UniSA Bldg, cnr North Terrace & Morphett St bridge, GPO Box 2471 Adelaide SA 5001, +61 8 8302 7751, Gregory.Goodall@unisa.edu.au
  • Associate Professor Philip Gregory (Head, Gene Regulation in Cancer Laboratory), Centre for Cancer Biology, SA Pathology and University of South Australia UniSA Bldg, cnr North Terrace & Morphett St bridge, GPO Box 2471 Adelaide SA 5001, +61 8 8302 7829, Philip.Gregory@unisa.edu.au

Software

MS Office

R-studio

GraphPad

Google Drive and G Suite

Overview

1
1

8

Languages

English
Bilingual or Proficient (C2)
Thai
Bilingual or Proficient (C2)

Timeline

Research Scientist I

Lucence Diagnostic Pte. Ltd.
11.2021 - 7 2023

Ph.D. - Biochemistry (International Program)

Mahidol University
04.2001 -

Ph.D. - Research Scholar

University of South Australia
04.2001 -

Bachelor of Science - Biology

Kasetsart University
04.2001 -

Research Scientist II

Lucence Diagnostic Pte. Ltd.
7 2023 - Current

Similar Profiles

CREATE PROFILE
Pannapa PinwehaResearch Scientist II